| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Over the last 12 months, insiders at Armata Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Armata Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Armata Pharmaceuticals, Inc. have bought $49M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,385,208 shares for transaction amount of $26.93M was made by Innoviva Strategic Opportunities LLC () on 2022‑03‑31.
| 2022-03-31 | Innoviva Strategic Opportunities LLC | 5.39M 15.2956% | $5.00 | $26.93M | -26.79% | |||
| 2022-02-09 | Innoviva, Inc. | director | 3.61M 12.27% | $5.00 | $18.07M | -21.85% | ||
| 2021-10-29 | Innoviva, Inc. | 1.21M 5.1858% | $3.30 | $4M | +33.75% | |||
| 2021-03-17 | Innoviva, Inc. | 4.29M 12.3568% | $3.25 | $13.93M | -25.41% | |||
| 2021-01-26 | Innoviva, Inc. | 1.87M 8.1521% | $3.25 | $6.07M | +13.46% | |||
| 2020-03-27 | Innoviva, Inc. | 10 percent owner | 7.72M 66.226% | $2.87 | $22.15M | +7.19% | ||
| 2018-03-22 | PERRY MICHAEL S | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | ||
| 2018-03-22 | COOK JEREMY CURNOCK | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | ||
| 2017-09-19 | PERRY MICHAEL S | director | 105,015 – | $0 | $0 | +11.11% | ||
| 2017-09-19 | COOK JEREMY CURNOCK | director | 105,015 – | $0 | $0 | +11.11% | ||
| 2017-06-29 | PERRY MICHAEL S | director | 5,757 – | $0 | $0 | +43.42% | ||
| 2017-06-29 | COOK JEREMY CURNOCK | director | 5,757 – | $0 | $0 | +43.42% | ||
| 2016-12-29 | Sale | KIRK RANDAL J | 10 percent owner | 42,000 0.3166% | $0.45 | $18,900 | -76.14% | |
| 2016-12-28 | Sale | KIRK RANDAL J | 10 percent owner | 84,620 0.6272% | $0.47 | $39,771 | -77.53% | |
| 2016-12-27 | Sale | KIRK RANDAL J | 10 percent owner | 50,400 0.3723% | $0.51 | $25,704 | -79.36% | |
| 2016-11-22 | COOK JEREMY CURNOCK | director | 46,666 4.0827% | $7.40 | $345,328 | -81.77% | ||
| 2016-06-21 | COOK JEREMY CURNOCK | director | 15,057 – | $0 | $0 | -70.18% | ||
| 2016-04-08 | COOK JEREMY CURNOCK | director | 171,298 – | $0 | $0 | -61.41% | ||
| 2015-10-06 | DRAPEAU LOUIS | director | 10,000 0.1764% | $4.39 | $43,900 | -31.52% | ||
| 2015-10-05 | Salka Michael Scott | Chief Executive Officer | 4,200 0.0834% | $4.75 | $19,950 | -28.73% |
| Innoviva Strategic Opportunities LLC | 16365969 44.5808% | $95.58M | 1 | 0 | <0.0001% | |
| BIOGEN IDEC INC | 10 percent owner | 11704095 31.8819% | $68.35M | 1 | 23 | |
| ELAN CORP PLC | 10 percent owner | 11626282 31.6699% | $67.9M | 1 | 3 | |
| Innoviva, Inc. | director | 10980761 29.9115% | $64.13M | 5 | 0 | +1.43% |
| KIRK RANDAL J | 10 percent owner | 674169 1.8364% | $3.94M | 1 | 3 | |
| COOK JEREMY CURNOCK | director | 411105 1.1198% | $2.4M | 7 | 0 | <0.0001% |
| PERRY MICHAEL S | director | 411105 1.1198% | $2.4M | 3 | 0 | <0.0001% |
| PARKER H STEWART | President & CEO | 31175 0.0849% | $182,062.00 | 1 | 0 | |
| DRAPEAU LOUIS | director | 10000 0.0272% | $58,400.00 | 1 | 0 | |
| Salka Michael Scott | Chief Executive Officer | 4200 0.0114% | $24,528.00 | 1 | 0 | |
| Johnson Wendy S. | Interim Chief Operating Office | 1000 0.0027% | $5,840.00 | 1 | 0 | |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 0 0% | $0 | 0 | 15 |
$9,405,928 | 107 | 12.61% | $205.29M | |
$6,125,624 | 95 | -6.06% | $234.12M | |
$7,147,964 | 34 | 24.77% | $205.04M | |
$63,049,419 | 31 | 2.87% | $242.72M | |
$38,621,826 | 31 | 1.43% | $212.14M | |
$95,303,339 | 30 | -13.78% | $206.39M | |
$6,979,075 | 22 | -28.22% | $221.44M | |
$448,999,793 | 15 | -19.99% | $208.91M | |
$4,907,492 | 15 | -2.28% | $215.13M | |
$17,741,707 | 13 | 30.23% | $246.45M | |
$15,799,576 | 12 | -39.52% | $233.11M | |
$43,398,129 | 9 | 93.09% | $215.12M | |
Armata Pharmaceuticals, Inc. (ARMP) | $91,549,696 | 8 | -6.55% | $214.39M |
$145,296,407 | 8 | -0.98% | $212.08M | |
$99,355,998 | 7 | -65.74% | $229.68M | |
$20,729,984 | 5 | 51.71% | $194.22M | |
$110,261 | 3 | -45.30% | $209.46M | |
$15,551,156 | 3 | 98.82% | $186.87M | |
$16,003,671 | 3 | 55.38% | $219.39M |
| Increased Positions | 23 | +104.55% | 491,084 | +64.64% |
| Decreased Positions | 5 | -22.73% | 3,230 | -0.43% |
| New Positions | 12 | New | 321,924 | New |
| Sold Out Positions | 4 | Sold Out | 3,130 | Sold Out |
| Total Postitions | 40 | +81.82% | 1M | +64.21% |
| Vanguard Group Inc | $1,949.00 | 0.83% | 297,038 | +36,965 | +14.21% | 2025-09-30 |
| Geode Capital Management, Llc | $686.00 | 0.29% | 104,546 | 0 | 0% | 2025-09-30 |
| Edgewood Management Llc | $656.00 | 0.28% | 100,000 | 0 | 0% | 2025-09-30 |
| Bridgeway Capital Management, Llc | $293.00 | 0.12% | 44,682 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $271.00 | 0.12% | 41,296 | +2,400 | +6.17% | 2025-09-30 |
| State Street Corp | $264.00 | 0.11% | 40,300 | 0 | 0% | 2025-09-30 |
| Seacrest Wealth Management, Llc | $229.00 | 0.1% | 34,954 | 0 | 0% | 2025-09-30 |
| Grey Ledge Advisors, Llc | $197.00 | 0.08% | 30,000 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $175.00 | 0.07% | 26,666 | +748 | +2.89% | 2025-09-30 |
| Northern Trust Corp | $126.00 | 0.05% | 19,273 | 0 | 0% | 2025-09-30 |